Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for cannabis and alcohol dependence
ACTRN12610000742077Phase 3Recruiting
- Sponsor
- University of Sydney
- Start
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cannabis use disorder (CUD) and alcohol dependence comparing Oxytocin with Placebo (2 arms). Primary endpoints: Reduction in cannabis and associated alcohol craving and withdrawal and Diagnostic criteria for cannabis and alcohol dependence and substance consumption. Started Apr 2010; status: recruiting.
02
Drugs
oxytocin
03
Conditions
cannabis use disorder (CUD)alcohol dependence
Beyond the preview
Go deeper on ACTRN12610000742077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000742077.